Symbion Funding: How Much Did They Raise & Key Investors

How Much Did Symbion Raise?
Funding & Key Investors

Symbion, a long-standing wholesale retailer for pharmaceutical supplies, has secured $108M in major enterprise-level funding. This significant capital infusion includes a recent $108M strategic investment, underscoring the company's established market presence and future growth potential in the pharmaceutical distribution sector.

What is Symbion?

Symbion

Retail

Drug Stores & Pharmacies

Founded in 1845 and headquartered in Australia, Symbion operates as a key wholesale retailer within the pharmaceutical supply chain. The company's extensive history and focus on distributing pharmaceutical supplies position it as a critical intermediary between manufacturers and healthcare providers, ensuring the availability of essential medicines and health products across its operational regions.

How much funding has Symbion raised?

Symbion has raised a total of $108M across 1 funding round:

2004

Stock Offering

$108M

Stock Issuance/Offering (2004): $108M, investors not publicly disclosed

What's next for Symbion?

The substantial enterprise-level backing and recent strategic investment signal a new phase of development for Symbion. This capital is likely to be directed towards enhancing supply chain efficiencies, expanding its product portfolio, and potentially exploring new market opportunities within the pharmaceutical distribution landscape. The company's deep roots and established infrastructure provide a strong foundation for leveraging this financing to drive innovation and solidify its competitive advantage.

See full Symbion company page

See More Financial Insights